# 2018 ISPE-CCFDIE China Conference Agenda

Oct 16 Morning		Plenary	meeting	
Oct 16 Afternoon	Center for Food and Drug Inspection Session			
Oct 17 Morning	Forum A Oversea Regulation Updates	Forum B ( Manufacturing Prepa	g of Oral Solid	Forum C Quality Control Points of Cell Therapy Products
Oct 17 Afternoon	Forum D New Trends in Drug R&D and Consistency Evaluation	10101112111	armaceutical d Engineering ology	Forum F GxP Compliance and Corroboration Practice
Oct 18	Forum G Clinical Supply M	<b>1</b> anagement	ICH (	GMP ( Q7 ) Seminar

## Oct 16 Morning

Plenary meeting Host Kecheng Za	ang, Center for Food and Drug Inspection, CFDA
	Opening Ceremony
	Leader of Jiangsu Food and Drug Administration
09:00 - 09:20	Bin Xue, Director-General, China Center for Food and Drug International Exchange, CFDA
	Jiangping Dong, Deputy Director-General, Center for Food and Drug Inspection, CFDA
	Timothy P. Howard, Chairman of the ISPE International Board of Directors
00.20 00.50	New Situation of Pharmaceutical Production Safety in China
09:20 - 09:50	Department of Drug Safety Supervision, CFDA
00.50 10.20	New Measures for FDA drug regulation
09:50 - 10:20	Lane Christensen, FDA China Office
10:20 - 10:40	Break
10.40. 11.20	Introduction of ISPE Technical Documents
10:40 - 11:20	Timothy P. Howard, Chairman of the ISPE International Board of Directors
11 20 12 05	Policy of Stimulating and Promoting the Development of Pharmaceutical Industry in China
11:20 - 12:05	Rong Shao, Executive Vice Dean, Graduate School, China University of Pharmacy

#### Oct 16 Afternoon

	nd Drug Inspection Session ng, Center for Food and Drug Inspection, CFDA
13:30 - 14:15	Value and Trend of Drug Inspection  Jiangping Dong, Deputy Director-General, Center for Food and Drug Inspection, CFDA
14:15 - 15:00	Progress in Inspection of Drug Clinical Trial  Xue Qian, Director, Center for Food and Drug Inspection, CFDA
15:00 - 15:15	Break
15:15 - 16:00	Drug Inspection Report 2017 Yi Cao, Director, Center for Food and Drug Inspection, CFDA
16:00 - 16:45	On-site Inspection on Registration and Production Tiewei Zhai, Center for Food and Drug Inspection, CFDA
16:45 - 17:10	Q&A

### Oct 17 Morning

	Regulation Updates Ia, Jim Lambert
00.20 00.00	How the Innovations in Filtration Technologies Help to Comply with Recent International Regulatory Trends
08:30 - 09:00	Artem Gurvich, Sartorius market development manager
00.00 00.25	U.S. Regulation Update
09:00 - 09:35	Jim Lambert, CAI vice president
09:35 - 10:15	EU Regulation Update
09:33 - 10:13	Massimo Eli, ISPE Headquarters Specialist
10:15 - 10:30	Break
10.20 11.00	New Development of ICH
10:30 - 11:00	ISPE Headquarters Specialist
11.00 11.20	Research on Implementation of ICH in China
11:00 - 11:30	Yalin Liu, ICH China Office, Center for Drug Evaluation, CFDA
11 20 12 00	Application of ICH Q5 in Biopharmaceuticals
11:30 - 12:00	Zhengyu Dong, Henlius vice president
12:00 - 12:20	Panel Discussion

	Forum B Continuous Manufacturing of Oral Solid Preparation  Host Jue Lin, Eli Lilly		
08:30 - 09:00	Application of Simulation Technology in Experimental-to-Production Process of Compacting Machine  Qiping Zheng, Truking		
09:00- 09:30	Inspection Perspective on the Application of Emerging Technology Shuang Liu, Center for Food and Drug Inspection, CFDA		
09:350- 10:30	Development and Application of Continuous Manufacturing  Xiaoyu Zhang, David Pappa, Lilly Scientist		
10:30 - 10:45	Break		
10:45 - 11:15	Regulatory Requirements and Strategy of Continuous Manufacturing in Drug Registration  Jole Rodriguez, Eli Lilly Chief Scientist		
11:15 - 11:45	Regulatory Requirements for Continuous Manufacturing and on-site Inspection Points  David Mota, Eli Lilly Scientist		
11:45 - 12:15	Q&A		

Forum C Quality Control of Cell Therapy Products  Host Richard Wang, CEO, Fosun Kite Biotechnology Co., Ltd		
08:30 - 09:00	Considerations of On-site Inspection for Biologicals Yan Zhou, Center for Food and Drug Inspection, CFDA	
09:00- 09:30	Quality Control of Raw Materials and Excipients and Process Validation for Cell Therapy Products National Institutes for Food and Drug Control, CFDA	
09:30 - 10:00	Inspection of Cell Therapy Products in EU Annigje Rietveld, Former Dutch FDA inspector	
10:00 - 10:15	Break	
10:15 - 10:45	Challenges with Manufacture and Testing of Gene Modified Cell Therapy Products Mehrshid Alai-Safar, Kite pharmaceutical	
10:45 - 11:15	Registration Process and Quality Management of CTL-019  Rose Gao, Novartis pharmaceutical	
11:15 - 11:45	Some considerations for Cell Therapy Manufacturing Process Inspection Zhuoyu Ni, GE Healthcare	
11:45 - 12:30	Panel Discussion: Significance of industrialization for cell therapy products quality	

#### Oct 17 Afternoon

Forum D New Tro	ends in Drug R&D and Consistency Evaluation g, PAREXEL
13:30 - 14:00	Application of National Health Care Big DataPlatform Hui Xiao, Vice President, China Electric Data Service Co., Ltd
14:00 - 14:30	Full Cycle Evaluation of Drugs based on Clinical Value  Long Cheng, PAREXEL
14:30 - 15:00	Application of Complex Survival Analysis Model to Evaluate nonlinear effects of the factors affecting overall survival rate and its dynamic effects  Naiqing Zhao, Professor, Fudan University
15:00 - 15:30	The Key Role of Oral Solid Process Equipment in Consistency Evaluation and the Considerations of Process Amplification  Zhizhen He, General Manager, Chanse Mechatronics
15:30 - 15:45	Break
15:45 - 16:15	Experience Sharing in Consistency Evaluation Wanhe Deng, Registration Director, Johnson (China)
16:15 - 16:45	How to Develop Consistency Evaluation of Medicinal Excipients  Yong Bi, Anhui Sunhere Pharmaceutical Excipients Co.
16:45 – 17:10	Panel Discussion

Forum E Pharmaceutical Production and Engineering Technology HOST Ping Zhang, Lei Zhu, Sanofi	
13:30 - 14:00	Smart Automation Solutions for Bioprocess Control System
	Guofeng Xu, Thermo-Fisher
14:00 - 14:30	MAH introduction in US and EU
14.00 - 14.50	Daniel Zang, Sanofi China
14:30 - 15:00	Quality Culture
14.30 - 13.00	Xuelin Yin, Boehringer Ingelheim
	How to develop and qualify a scalable, robust single use process in
15:00 - 15:30	biomanufacturing process
	Siyi Liao, Merck
15:30 - 15:45	Break
15:45 - 16:15	Application of ICH Q7 in API production
	Ervin Vajda, Sanofi Hungary

16:15 - 16:45	Impact of Process Induced crystal transformation on Pharmaceutical Formulation  Jun Han, Shandong Liaocheng University
16:45 - 17:15	Computerized System Validation Life Cycle Ping Niu, Abbott
17:15 - 17:45	Strategy for Comparability Research of Biologicals Kochling, Sanofi US
17:45 - 18:00	Panel Discussion

Forum F GxP Compliance and Corroboration Practice  Host Xin Zhang, Austar		
13:30 - 14:15	QbD-based Biosimilar Research and Development Scott Liu, President and CEO of Henlius	
14:15 - 15:00	Investigation and Research on Laboratory OOS  Hongyang Li, Novartis	
15:00 - 15:15	Break	
15:15 - 15:45	The Whole Process Automates the Raw Material Drug Lean Production Xin Wang, Vice President, Qilu Pharmaceutical	
15:45 - 16:15	New Concept of Verification and Validation based on ASTM E2500 and Current Regulations in Pharmaceutical Industry Zhengxian Ke, Austar	
16:15 - 16:45	Application of Sterile Technology Simulation Test in Aseptic Liquid Medium Haiyi Chai, Nodbio	
16:45 - 17:15	Optimization and Amplification Strategy of Process Engineering from GLP  Laboratory to GMP Pilot-scale Test and cGMP Production  Xiaovun Dai, Vice Chairman of China Medical Biotechnology Association	
17:15 - 17:45	Panel Discussion	

### Oct 18 Morning

Forum G Clinica Host Lin Wang	al Supply Management
8:45 - 9:00	Forum Introduction Lin Wang
9:00 - 9:30	China GMP Regulation on Clinical Supply Management: Catalent's Experience LEO Zhang, Head of APAC Quality, Catalent
9:30 - 10:00	Regulatory, Clinical and Supply Chain Challenges of ATMPs (Cell and Gene Therapies)  Andrea Zobel, Senior Director, PAREXEL global clinical trail supply
10:00 - 10:15	Break
10:15 - 10:45	Regulatory Requirement and Ethical Review in Clinical Supply Management Li Yang, Director, Peking University Third Hospital
10:45 - 11:15	Regulatory, Clinical, Technological and Supply Chain Challenges of Direct-to-Subject Trials  Jeff Ten, Head of APAC clinical trial supply, PAREXEL
11:15 - 11:45	CSM Strategy and Local Practices Paul Cao, General Manager, ClinsChain (shanghai) Clinical Services
11:45 - 12:15	Panel Discussion: Interpretation of CFDA GMP Guide for CTM (draft)  Speakers and Center for Food and Drug Inspection, CFDA

ICH GMP (Q7) Seminar Host Kecheng Zang, Center for Food and Drug Inspection, CFDA		
08:30 - 08:40	Welcome Speech Pending	
08:40 - 10:40	ICH Q7 Introduction Stephan Ronninger EWG Expert	
10:40 - 11:00	Break	
11:00 - 12:00	Laboratory Control including Data Integrity according to ICH Q7  Dinesh Khokal EWG Expert	

#### Oct 18 Afternoon

ICH GMP (Q7) Seminar  Host Kecheng Zang, Center for Food and Drug Inspection, CFDA	
13:00 - 14:00	CFDI Inspectors' perspective on GMP of APIs including comparison of ICH Q7 and Chinese GMP Tiewei Zhai, Center for Food and Drug Inspection, CFDA
14:00 - 14:45	Local company perspective on GMP of APIs and experience sharing
14:45 - 15:00	Break
15:00 - 15:45	Supervision and inspection of APIs  Meng Yu, Jiangsu Food and Drug Administration
15:45 - 16:45	Recent Quality topics in the implementation of GMPS for APIs——Cleaning Validation Ervin Vajda, Sanofi Hungary
16:45 - 17:15	Q&A Session